Aclaris Therapeutics, Inc. (ACRS) FDA catalysts & readout calendar
Updated ·next FDA decision on the calendar
We do not currently track a confirmed FDA catalyst for Aclaris Therapeutics, Inc.. Any decision listed below was inferred from share-price behaviour and has not been checked against a filing, so there is nothing we have verified to show here yet.
Aclaris Therapeutics, Inc. · no upcoming catalyst on file · 0 past FDA decisions
This page aggregates ACRS's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Common questions
When is the next FDA decision for Aclaris Therapeutics, Inc. (ACRS)?
Aclaris Therapeutics, Inc. has no dated FDA catalyst on our calendar right now. That means no scheduled decision or readout date has been published in a source we can point to, not that none exists. We would rather say that than estimate one.
How do stocks like ACRS move into an FDA decision?
We have no measured history for ACRS itself. Across the whole study of 1,855 FDA decisions, the median stock rose 17.9% at its best point in the 120 trading days before the decision, but was only 2.2% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
Where does this ACRS data come from?
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.